Complicaciones del tratamiento y de la propia infección
Eugènia Negredo
Fundació Lluita contra la Sida
Hospital Universitari Germans Trias i Pujol
Barcelona
5 Març 2015
CARDIOVASCULAR
Plenary 134 (Inflamación)
Oral abstracts 136-140
Themed Discussion 746-749, 750-751 (Guías ACC/AHA)
Posters 729-751
739 Impact of Antiretroviral Drugs on Hypertension in HIV-Positive Persons: D:A:D Study Camilla I. Hatleberg (P Reiss; W El-Sadr; J. Lundgren… D:A:D Study )
D:A:D study. 33.278 pacientes���� 7636 (22,9%) HTA
1.71
1.33
1.95
The model was adjusted for age, sex, race, HIV
transmission risk, calendar year, cigarette smoking,
hypertension, diabetes, renal impairment, high total
cholesterol, high triglycerides, statin use, CD4 count, HIV
viral load, previous PI use, and cohort, all measured prior
to, or at the time of study entry (which was ABC initiation
for ABC users).
140 Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors Grace A. McComsey (ACTG 5257 substudy)
733 Rosuvastatin vs PI Switch for Hypercholesterolemia: Randomised Trial Frederick J. Lee (J. Hoy; E Martinez; A Carr…)
6 centros Australia + BarcelonaRandomizado: - Añadir rosuvastatina 10mg/d + IP (n=23)
- Cambio IP por raltegravir o rilpivirina o atazanavir (no potenciado) (n=20)12 semanas seguimiento.
Fasting total cholesterol >5.5 mmol/L (>213 mg/dL)
Framingham risk score ≥8% at 10 years OR DM OR a family history of premature coronary artery
disease in a first-degree relative
INFLAMACIÓN
Oral abstracts 47-48
Themed Discussion 778 (inflamación y obesidad)
Posters 312-323 (predictores de evolución y mortalidad)
752-756 (asociación a aterosclerosis)
761-764
134 Cardiovascular Disease in HIV Patients: An Emerging Paradigm and Call to Action Steven Grinspoon
#752 – 756
Asociación inflamación con aterosclerosis
136 Statin Therapy Reduces Coronary Noncalcified Plaque Volume in HIV Patients: A Randomized Controlled Trial Janet Lo, Grinspoon Randomization: - N=72 Rosuvastatin
- N=75 placebo
137 Rosuvastatin Arrests Progression of Carotid Intima-Media Thickness in Treated HIV Grace A. McComsey
FDG PET/TCRandomization: - N=19 Atorvastatin 20mg
- N=21 placebo
HUESO
Oral abstracts 141 (FRAX subestima riesgo)Oral abstracts 141 (FRAX subestima riesgo)
Posters 765-777
776 Heel Quantitative Ultrasound to Cut Down on DXA Costs in HIV-infected Patients Marilia R. Pinzone
Quantitative ultrasound (QUS) of the heel is a radiation-free, easy-to-perform technique,
which has been proposed as an alternative method to DXA for assessing bone status.
Cross-sectional study 244 HIV-infected patients.
769LB Less Bone Loss With a Maraviroc Regimen in HIV-Infected Treatment-Naïve Babafemi Taiwo (Tsibris; Eron; Brown,…ACTG A5303 Study Team)
ACTG A5303 Study: Phase II, double-blind, placebo-controlled, 48 week study
766 Bone Turnover on DRV/r + Either RAL or TDF/FTC as First-Line ART: NEAT 001 / ANRS 143 Jose I Bernardino (Mocroft; Arribas1; Raffi… NEAT study)
DRV/r+RAL (N=65) vs DRV/r+TDF/FTC (N=68)DRV/r+RAL was associated with significantly less BMD loss than DRV/r+TDF/FTC (ICAAC 2014,H1198)
767 Tenofovir Replacement in Patients With Osteoporosis Increased Sclerostin Levels Eugenia Negredo (osteoTDF study)
142 Exposure to Antiretrovirals and Development of Chronic Kidney Disease (CKD) Amanda Mocroft (D:A:D Study Group)
Tras 6 años de exposición, el
riesgo relativo de ERC se
incrementó en
- 97% para TDF,
- 320% para ATV/r
- 140% para LPV/r.
795 Safety of Tenofovir Alafenamide in Renal Impairment Anton Pozniak Tailandia, España, Inglatera, US